Abstract
Introduction: Hematide™, a novel synthetic PEGylated peptidic compound, binds to and activates the erythropoietin receptor. It is being developed for the treatment of anemia associated with chronic kidney disease and cancer.
Objective: To assess the subcutaneous (SC) Hematide™ dose required to increase hemoglobin (Hgb) by ≥1 g/dL in anemic cancer patients on chemotherapy. Safety, PD and PK assessment of Hematide™ are also planned.
Method: In an ongoing phase 2, openlabel, multicenter, dosefinding study, Hematide™ is being given SC in 15 patient cohorts every 3 wks for 4 doses. The initial dose is 0.10 mg/kg. Entry criteria include confirmed solid tumor malignancy or lymphoma, ≥9 weeks of chemotherapy, baseline (BL) Hgb ≥8 and <11 g/dL, and adequate iron, folate, and B12 stores.
Results: Preliminary results are presented for the 1st cohort. Mean body weight for the 8 female and 7 male patients was 67.8Kg. Nine out of 15 patients completed 12 weeks follow-up. Six patients terminated early for non-study drug related SAEs (2), remission of cancer (1), or transfusions (3, Hgb values posttransfusion excluded from this report) . Week 7: 10 patients completed Week (Wk) 7 with data available. Their mean ± SD Hgb increased from BL by 1.6 ± 1.8 g/dL. Seven had a ≥1.0 g/dL Hgb increase (range 1.7–3.7 g/dL) at Wk 7. Of the remaining 3 patients, 2 had a Hgb increase of 1.65 and 1.1 g/dL, respectively at Wk 9; the 3rd had a Hgb increase of 1.7 g/dL at Wk 12. One patient with missing Wk 7 data had Hgb increases of 1.8 and 3.4 g/dL at Wk 6 and 9 respectively. Week 9: 11 patients had Wk 9 data that show a mean ±SD Hgb increase from baseline of 2.2 ±1.79 g/dL. Of these, 10 had Hgb increases of ≥1.0 g/dL (range 1.1–5.2 g/dL). The one patient who did not have ≥1.0 g/dL Hgb increase at Wk 9 had a Hgb increase of 1.7 g/dL at Wk 12. Four SAEs (none related to study drug) were reported in 3 patients.
Conclusion: Preliminary data from the 1st cohort indicate that Hematide™ given every 3 wks appears to be well tolerated and results in an increase in Hgb of ≥ 1g/dL by Wk 7 in the majority of this study population. Additional data will be presented as it becomes available.
Disclosures: C. Andresen, S. Chang, AM Duliege, R. Leong are employees of Affymax Inc., the company that is developing this investigational compound.; R. Stead is a consultant of Affymax Inc.; C. Andresen, S. Chang, AM Duliege, R. Leong, R. Stead have stock options in Affymax Inc.; All authors other then those listed above are investigators in the study and receive financial compensation for the conduct of the trial.; R. Stead receives honoraria from Afftymax Inc. as a consultant to this company.; R. Stead is a member of Affymax Inc. advisory committee.
Author notes
Corresponding author
